Lupin 2024

ADHD

Impax to introduce Adderall XR generic

Impax to introduce Adderall XR generic

HAYWARD, Calif. — Impax Laboratories Inc. has received Food and Drug Administration approval for dextroamphetamine saccharate, amphetamine aspartate monohydrate, dextroamphetamine sulfate and amphetamine sulfate extended-release capsules, mixed amphetamine product used for the treatment of attention deficit hyperactivity disorder (ADHD). Impax said Wednesday that its mixed amphetamine product, a CII controlled substance, comes in dosages of

Mylan, Teva roll out generic versions of Intuniv

Mylan, Teva roll out generic versions of Intuniv

NEW YORK — Mylan N.V. and Teva Pharmaceutical Industries Ltd. have released guanfacine extended-release tablets, a nonstimulant medication for attention deficit hyperactivity disorder (ADHD), in the United States. The pharmaceutical companies said Tuesday that their products, available in strengths of 1 mg, 2 mg, 3 mg and 4 mg, are generic equivalents of Intuniv from

Centrum 7/6  banner